Decisions to authorise or withdraw authorisation taken in application of Article L. 1161-5 are published on the Agency’s website.
Decisions to withdraw programme authorisation may be accompanied by an obligation to provide information, the content of which has been approved in advance by the Agence nationale de sécurité du médicament et des produits de santé, and distributed by the operator, at its own expense, to the healthcare professionals, associations and patients concerned.